A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Active Ulcerative Colitis
Interventions
DRUG

BG9418 (Interferon beta-1a)

Avonex IM injection, self-administered per protocol

DRUG

Placebo

Placebo IM injection, self-administered per protocol.

Trial Locations (35)

35294

Investigator, Birmingham

73104

Investigator, Oklahoma City

80215

Investigator, Lakewood

06010

Investigator, Bristol

02481

Investigator, Wellesley Hills

T2N4N1

Investigator, Calgary

V1Y 2H4

Investigator, Kelowna

R3A1R9

Investigator, Winnipeg

Unknown

Investigator, Hradec Králové

Investigator, Ostrava

Investigator, Parbudice

Investigator, Prague

Investigator, Slaný

Investigator, Teplice

Investigator, Budapest

Investigator, Eger

Investigator, Szeged

Investigator, Székesfehérvár

Investigator, Lublin

Investigator, Pruszków

Investigator, Sopot

Investigator, Torun

Investigator, Warsaw

Investigator, Wroclaw

Investigator, Kazan'

Investigator, Krasnodar

Investigator, Lipetsk

Investigator, Moscow

Investigator, Nizhny Novgorod

Investigator, Rostov-on-Don

Investigator, Saint Petersburg

Investigator, Saratov

Investiator, Yaroslavl

Investigator, Nitra

Investigator, Trenčín

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00616434 - A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | Biotech Hunter | Biotech Hunter